For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge


Tucatinib improved survival for women in the HER2CLIMB trial, including some whose cancer had spread to the brain. Trastuzumab deruxtecan improved survival and shrank many tumors in the DESTINY-Breast01 trial, which led to its accelerated approval.

Powered by WPeMatico